PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Impact of the 21-gene recurrence score assay in clinical treatment and prognosis analysis for patients with hormone receptor positive early-stage breast cancer.

Abstract The 21-gene RS is related to tumor grade, ER, PR and Ki-67 index. RS is an independent risk factor for RFS in patients with hormone receptor positive early-stage breast cancer.
PMID
Related Publications

Evaluation of Oncotype DX Recurrence Score as a prognostic factor in Japanese women with estrogen receptor-positive, node-negative primary Stage I or IIA breast cancer.

West German Study Group Phase III PlanB Trial: First Prospective Outcome Data for the 21-Gene Recurrence Score Assay and Concordance of Prognostic Markers by Central and Local Pathology Assessment.

Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.

Impact of the 21-gene recurrence score assay compared with standard clinicopathologic guidelines in adjuvant therapy selection for node-negative, estrogen receptor-positive breast cancer.

21-Gene Recurrence Score and Locoregional Recurrence in Node-Positive/ER-Positive Breast Cancer Treated With Chemo-Endocrine Therapy.

Authors

Mayor MeshTerms
Keywords

21-gene assay

Breast neoplasms

Prognosis

Recurrence score

Journal Title zhonghua zhong liu za zhi [chinese journal of oncology]
Publication Year Start




PMID- 29502370
OWN - NLM
STAT- MEDLINE
DCOM- 20180313
LR  - 20180313
IS  - 0253-3766 (Print)
IS  - 0253-3766 (Linking)
VI  - 40
IP  - 2
DP  - 2018 Feb 23
TI  - [Impact of the 21-gene recurrence score assay in clinical treatment and prognosis
      analysis for patients with hormone receptor positive early-stage breast cancer].
PG  - 110-114
LID - 10.3760/cma.j.issn.0253-3766.2018.02.006 [doi]
AB  - Objective: To explore the association between the 21-gene recurrence score (RS)
      and clinicopathologic characteristics as well as prognosis in patients with
      axillary lymph node negative, hormone receptor (HR) positive breast cancer.
      Methods: The clinicopathologic data of 439 early breast cancer patients who
      underwent 21 gene RS testing was retrospectively analyzed. According to the 21
      gene RS, the patients were divided into low risk (295 cases), intermediate risk
      (111 cases) and high-risk (33 cases) group. The relationship between the 21 gene 
      RS and clinicopathological characteristics, treatment, recurrence and metastasis 
      was analyzed. Univariate and multivariate statistical analyses were used to
      analyze the risk factors for relapse free survival (RFS). Results: Tumor grade,
      estrogen receptor (ER), progesterone receptor (PR) and Ki-67 index were
      significantly different among the 3 risk cohorts (P<0.001 for all). After a
      median follow-up of 32 months, the recurrence rate in low risk group (3.7%) was
      significantly lower than that in the intermediate-high risk group (9.0%), the
      locoregional recurrence (LRR) rate of low, intermediate and high risk group was
      2.4%, 6.3% and 9.1%; and the distant metastasis (DM) rate in low risk group was
      1.4% and 2.1% in the intermediate-high risk group. Univariate analysis showed RS,
      ER status and endocrine therapy were prognostic factors for RFS (P<0.05 for all).
      Multivariate analysis showed that RS was an independent significant predictor for
      RFS (P=0.04). Conclusions: The 21-gene RS is related to tumor grade, ER, PR and
      Ki-67 index. RS is an independent risk factor for RFS in patients with hormone
      receptor positive early-stage breast cancer.
FAU - Zhang, Y N
AU  - Zhang YN
AD  - Department of Breast Surgery, Peking Union Medical College Hospital, Chinese
      Academy of Medical Sciences and Peking Union Medical College, Beijing 100730,
      China.
FAU - Zhou, Y D
AU  - Zhou YD
FAU - Mao, F
AU  - Mao F
FAU - Guan, J H
AU  - Guan JH
FAU - Lin, Y
AU  - Lin Y
FAU - Wang, X J
AU  - Wang XJ
FAU - Shen, S J
AU  - Shen SJ
FAU - Wang, C J
AU  - Wang CJ
FAU - Yao, R
AU  - Yao R
FAU - Sun, Q
AU  - Sun Q
LA  - chi
PT  - Journal Article
PL  - China
TA  - Zhonghua Zhong Liu Za Zhi
JT  - Zhonghua zhong liu za zhi [Chinese journal of oncology]
JID - 7910681
RN  - 0 (Ki-67 Antigen)
RN  - 0 (Receptors, Estrogen)
RN  - 0 (Receptors, Progesterone)
RN  - 0 (progesterone receptor B)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Analysis of Variance
MH  - Breast Neoplasms/chemistry/*genetics/pathology/therapy
MH  - Female
MH  - Humans
MH  - Ki-67 Antigen/analysis
MH  - Neoplasm Recurrence, Local/*genetics
MH  - Prognosis
MH  - Receptor, ErbB-2/analysis
MH  - Receptors, Estrogen/analysis
MH  - Receptors, Progesterone/analysis
MH  - Retrospective Studies
MH  - Risk
MH  - Risk Factors
OTO - NOTNLM
OT  - 21-gene assay
OT  - Breast neoplasms
OT  - Prognosis
OT  - Recurrence score
EDAT- 2018/03/06 06:00
MHDA- 2018/03/14 06:00
CRDT- 2018/03/06 06:00
PHST- 2018/03/06 06:00 [entrez]
PHST- 2018/03/06 06:00 [pubmed]
PHST- 2018/03/14 06:00 [medline]
PST - ppublish
SO  - Zhonghua Zhong Liu Za Zhi. 2018 Feb 23;40(2):110-114.